Identification of NY-ESO-1 Peptide Analogues Capable of Improved Stimulation of Tumor-Reactive CTL
Ji‐Li Chen(John Radcliffe Hospital), Vincenzo Cerundolo(John Radcliffe Hospital), P. Rod Dunbar(Memorial Sloan Kettering Cancer Center), Elke Jäger(Krankenhaus Nordwest), Dennis Panicali(Fox Chase Cancer Center), Uzi Gileadi(John Radcliffe Hospital), Elisabeth Stockert(Memorial Sloan Kettering Cancer Center), Sacha Gnjatic(Tisch Hospital), Lloyd J. Old(Gynecologic Oncology Group), Alexander Knuth(National Center for Cancer Care and Research), Yasuhiro Nagata(Memorial Sloan Kettering Cancer Center), Yao‐Tseng Chen(Memorial Sloan Kettering Cancer Center)
Cited by 176
Related Papers
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Intraepithelial CD8 <sup>+</sup> tumor-infiltrating lymphocytes and a high CD8 <sup>+</sup> /regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
|Proceedings of the National Academy of Sciences|2005|2.4k
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
|New England Journal of Medicine|2012|2.1k